Quantitation and speciation of residual protein within active pharmaceutical ingredients using image analysis with SDS-PAGE.

Biocatalysis Densitometry Directed enzyme evolution Electrophoresis Pharmaceuticals Process research & development

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
05 Jan 2022
Historique:
received: 24 08 2021
revised: 20 09 2021
accepted: 22 09 2021
pubmed: 5 10 2021
medline: 16 11 2021
entrez: 4 10 2021
Statut: ppublish

Résumé

Recent advances in biocatalysis and directed enzyme evolution has led to a variety of enzymatically-driven, elegant processes for active pharmaceutical ingredient (API) production. For biocatalytic processes, quantitation of any residual protein within a given API is of great importance to ensure process robustness and quality, pure pharmaceutical products. Typical analytical methods for analyzing residual enzymes within an API, such as enzyme-linked immunosorbent assays (ELISA), colorimetric assays, and liquid chromatographic techniques, are limited for determining only the concentration of known proteins and require harsh solvents with high API levels for analysis. For the first time, total residual protein content in a small molecule API was quantitated using image analysis applied to SDS-PAGE. Herein, a proposed methodology for residual protein detection, quantitation, and size-based speciation is presented, in which an orthogonal technique is offered to traditional analysis methods, such as ELISA. Results indicate that our application of the analytical methodology is able to reliably quantitate both protein standards and the total residual protein present within a final API, with good agreement as compared to traditional ELISA results. Further, speciation of the residual protein within the API provides key information concerning the individual residual proteins present, including their molecular weight, which can lead to improved process development efforts for residual protein rejection and control. This analytical methodology thus offers an alternative tool for easily identifying, quantitating, and speciating residual protein content in the presence of small molecule APIs, with potential for wide applicability across industry for biocatalytic or directed enzyme evolution efforts within process development.

Identifiants

pubmed: 34607166
pii: S0731-7085(21)00504-5
doi: 10.1016/j.jpba.2021.114393
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0
Solvents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114393

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Joseph P Smith (JP)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA. Electronic address: joseph.smith@merck.com.

Nicole M Ralbovsky (NM)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Mackenzie L Lauro (ML)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Erik Hoyt (E)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Erik D Guetschow (ED)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Fengqiang Wang (F)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

John A McIntosh (JA)

Process Research & Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA.

Zhijian Liu (Z)

Process Research & Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA.

Ian Mangion (I)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Narayan Variankaval (N)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Xiaodong Bu (X)

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs

Comparative assessment of physics-based in silico methods to calculate relative solubilities.

Adiran Garaizar Suarez, Andreas H Göller, Michael E Beck et al.
1.00
Solvents Solubility Quantum Theory Molecular Dynamics Simulation Thermodynamics
Xanthones Garcinia mangostana Plant Extracts Solvents Chemical Precipitation

Classifications MeSH